Ocugen (OCGN) Other financing activities (2014 - 2026)

Ocugen's (OCGN) quarterly Other financing activities came in at $15.0 million in Q1 2026, up 2387.56% on a QoQ basis from $603000.0 in Q2 2021.

Analysis

Ocugen (OCGN) Other financing activities (2014 - 2026) Analysis & Trends

Ocugen (OCGN) has 9 years of Other financing activities data on file, last reported at $15.0 million in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (changed N/A YoY) and the FY2021 annual result came in at $603000.0, changed N/A from the prior year.
Other financing activities climbed to $15.0 million in Q1 2026, from $603000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $15.0 million in Q1 2026 to a low of $15.0 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Ocugen	458.91 Mn	358.81 Mn	-

Historic Data

Download Data